Home ETF List About

Portfolio Holdings Detail for ISIN IE00BYXG2H39
Stock Name / FundiShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
IssuerBlackrock
Entity holding fund iShares IV Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300ZP07LMR36K1T02
ETF TickerBTEC(USD) LSE
ETF TickerBTEK(GBP) LSE
ETF Ticker2B70(EUR) F
ETF Ticker2B70.DE(EUR) CXE
ETF TickerBTEC.LS(USD) CXE
ETF TickerBTEK.LS(GBP) CXE
ETF TickerBTEC.L(GBP) LSE
ETF TickerBTEK.L(GBP) LSE

Holdings detail for LXRX

Stock NameLexicon Pharmaceuticals Inc
TickerLXRX(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS5288723027

Show aggregate LXRX holdings

News associated with LXRX

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Given Average Rating of “Hold” by Analysts
Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX – Get Free Report) have earned a consensus rating of “Hold” from the five analysts that are currently covering the firm, Marketbeat.com reports. Three investment analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 1-year target price […] - 2025-07-10 05:48:56
HC Wainwright Reaffirms “Buy” Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX)
Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They currently have a $4.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s target price would indicate a potential upside of 344.44% from the stock’s current price. […] - 2025-06-26 02:48:53
Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Crosses Above 200 Day Moving Average – Here’s What Happened
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX – Get Free Report)’s share price passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.65 and traded as high as $0.75. Lexicon Pharmaceuticals shares last traded at $0.73, with a volume of 2,479,330 shares changing hands. Analyst Upgrades and Downgrades […] - 2025-06-24 05:14:58
Hennion & Walsh Asset Management Inc. Sells 33,201 Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)
Hennion & Walsh Asset Management Inc. lessened its position in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX – Free Report) by 3.8% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 830,054 shares of the biopharmaceutical company’s stock after selling 33,201 shares […] - 2025-06-09 05:32:51
Deutsche Bank AG Boosts Holdings in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)
Deutsche Bank AG increased its stake in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX – Free Report) by 378.0% in the fourth quarter, Holdings Channel reports. The institutional investor owned 315,659 shares of the biopharmaceutical company’s stock after acquiring an additional 249,616 shares during the quarter. Deutsche Bank AG’s holdings in Lexicon Pharmaceuticals were worth $234,000 as of […] - 2025-06-02 04:52:49
Woodline Partners LP Lowers Stock Holdings in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)
Woodline Partners LP cut its stake in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX – Free Report) by 81.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 229,376 shares of the biopharmaceutical company’s stock after selling 982,548 shares during the quarter. Woodline Partners […] - 2025-05-28 05:25:05
Contrasting Lexicon Pharmaceuticals (NASDAQ:LXRX) & Grifols (NASDAQ:GRFS)
Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free Report) and Grifols (NASDAQ:GRFS – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, dividends and institutional ownership. Profitability This table compares Lexicon Pharmaceuticals and Grifols’ net […] - 2025-05-26 02:20:56
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Stake Boosted by Invesco Ltd.
Invesco Ltd. grew its holdings in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX – Free Report) by 60.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 104,494 shares of the biopharmaceutical company’s stock after purchasing an additional 39,420 shares during the quarter. Invesco Ltd.’s […] - 2025-05-06 04:28:46
Lexicon Pharmaceuticals (NASDAQ:LXRX) Coverage Initiated by Analysts at StockNews.com
StockNews.com initiated coverage on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free Report) in a research report issued to clients and investors on Monday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock. A number of other analysts have also recently issued reports on the company. Needham & Company LLC reissued a “hold” […] - 2025-04-21 03:10:46
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives $3.67 Consensus PT from Analysts
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX – Get Free Report) has been given a consensus recommendation of “Hold” by the five brokerages that are presently covering the company, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average twelve-month price objective […] - 2025-04-04 02:12:45
Virtu Financial LLC Invests $66,000 in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)
Virtu Financial LLC purchased a new stake in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX – Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 88,982 shares of the biopharmaceutical company’s stock, valued at approximately $66,000. Other hedge funds and other […] - 2025-04-01 04:56:52
Swiss National Bank Grows Stock Holdings in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)
Swiss National Bank increased its stake in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX – Free Report) by 34.4% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 426,600 shares of the biopharmaceutical company’s stock after buying an additional 109,100 shares during the quarter. Swiss National Bank’s holdings in Lexicon Pharmaceuticals were worth $315,000 as of its […] - 2025-03-31 04:50:50
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives Consensus Rating of “Hold” from Analysts
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX – Get Free Report) has received a consensus rating of “Hold” from the five ratings firms that are covering the company, MarketBeat.com reports. Three investment analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 12-month price objective among brokerages […] - 2025-03-12 04:52:43
Lexicon Pharmaceuticals (NASDAQ:LXRX) Coverage Initiated by Analysts at StockNews.com
Equities research analysts at StockNews.com assumed coverage on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free Report) in a report issued on Wednesday. The firm set a “sell” rating on the biopharmaceutical company’s stock. A number of other equities analysts have also recently issued reports on the company. Piper Sandler cut their target price on […] - 2025-03-12 04:19:02
Piper Sandler Issues Pessimistic Forecast for Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Price
Lexicon Pharmaceuticals (NASDAQ:LXRX – Free Report) had its price objective lowered by Piper Sandler from $10.00 to $6.00 in a research report report published on Friday,Benzinga reports. The brokerage currently has an overweight rating on the biopharmaceutical company’s stock. Several other brokerages have also issued reports on LXRX. Leerink Partners reissued a “market perform” rating […] - 2025-03-10 04:58:47
Lexicon Pharmaceuticals (NASDAQ:LXRX) Rating Lowered to Hold at Leerink Partnrs
Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free Report) was downgraded by Leerink Partnrs from a “strong-buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday,Zacks.com reports. Other analysts have also recently issued reports about the company. Needham & Company LLC reaffirmed a “hold” rating on shares of Lexicon Pharmaceuticals […] - 2025-03-07 06:28:46

iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) LXRX holdings

DateNumber of LXRX Shares HeldBase Market Value of LXRX SharesLocal Market Value of LXRX SharesChange in LXRX Shares HeldChange in LXRX Base ValueCurrent Price per LXRX Share HeldPrevious Price per LXRX Share Held
2025-11-11 (Tuesday)242,712USD 378,631USD 378,631
2025-11-10 (Monday)242,712LXRX holding increased by 634USD 344,651LXRX holding increased by 42053USD 344,651634USD 42,053 USD 1.42 USD 1.25
2025-11-07 (Friday)242,078USD 302,598LXRX holding decreased by -43574USD 302,5980USD -43,574 USD 1.25 USD 1.43
2025-11-06 (Thursday)242,078LXRX holding increased by 633USD 346,172LXRX holding increased by 12978USD 346,172633USD 12,978 USD 1.43 USD 1.38
2025-11-05 (Wednesday)241,445USD 333,194LXRX holding increased by 12072USD 333,1940USD 12,072 USD 1.38 USD 1.33
2025-11-04 (Tuesday)241,445LXRX holding increased by 637USD 321,122LXRX holding decreased by -6377USD 321,122637USD -6,377 USD 1.33 USD 1.36
2025-11-03 (Monday)240,808USD 327,499LXRX holding decreased by -4816USD 327,4990USD -4,816 USD 1.36 USD 1.38
2025-10-31 (Friday)240,808USD 332,315LXRX holding increased by 9632USD 332,3150USD 9,632 USD 1.38 USD 1.34
2025-10-30 (Thursday)240,808LXRX holding increased by 3190USD 322,683LXRX holding increased by 6651USD 322,6833,190USD 6,651 USD 1.34 USD 1.33
2025-10-29 (Wednesday)237,618LXRX holding increased by 1274USD 316,032LXRX holding decreased by -7759USD 316,0321,274USD -7,759 USD 1.33 USD 1.37
2025-10-28 (Tuesday)236,344USD 323,791LXRX holding decreased by -4727USD 323,7910USD -4,727 USD 1.37 USD 1.39
2025-10-27 (Monday)236,344USD 328,518LXRX holding decreased by -7090USD 328,5180USD -7,090 USD 1.39 USD 1.42
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of LXRX by Blackrock for IE00BYXG2H39

Show aggregate share trades of LXRX

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-11-10BUY6341.4501.250 1.270USD 805 0.89
2025-11-06BUY6331.5251.390 1.404USD 888 0.89
2025-11-04BUY6371.3901.325 1.332USD 848 0.88
2025-10-30BUY3,1901.3701.303 1.310USD 4,178 0.87
2025-10-29BUY1,2741.3301.370 1.366USD 1,740 0.87
2025-10-22SELL-2,5241.3901.450 1.444USD -3,645 0.86 Loss of -1,483 on sale
2025-10-20BUY1,2621.5201.530 1.529USD 1,930 0.85
2025-10-17BUY3,1491.4201.460 1.456USD 4,585 0.85
2025-10-15BUY5,0001.5301.530 1.530USD 7,650 0.84
2025-10-03BUY4,4661.4101.460 1.455USD 6,498 0.84
2025-10-02BUY6381.3801.450 1.443USD 921 0.83
2025-09-30BUY1,2741.3501.390 1.386USD 1,766 0.83
2025-09-26BUY1,2761.4001.420 1.418USD 1,809 0.82
2025-09-25BUY1,2781.3401.370 1.367USD 1,747 0.82
2025-09-18BUY6481.2201.250 1.247USD 808 0.81
2025-09-17BUY1,9531.0901.110 1.108USD 2,164 0.81
2025-08-20SELL-2,5481.1301.160 1.157USD -2,948 0.80 Loss of -902 on sale
2025-07-30BUY2,5201.0201.100 1.092USD 2,752 0.79
2025-07-17SELL-1,2601.3501.430 1.422USD -1,792 0.77 Loss of -823 on sale
2025-07-11SELL-5,1121.0801.130 1.125USD -5,751 0.76 Loss of -1,878 on sale
2025-07-07BUY1,9260.8700.910 0.906USD 1,745 0.75
2025-07-02BUY35,3650.9200.930 0.929USD 32,854 0.75
2025-06-11BUY1,2920.7000.730 0.727USD 939 0.75
2025-06-10BUY1,2920.7000.740 0.736USD 951 0.75
2025-06-04SELL-6460.6600.700 0.696USD -450 0.75 Profit of 36 on sale
2025-04-23BUY6460.6700.690 0.688USD 444 0.78
2025-04-10SELL-5,1680.5000.540 0.536USD -2,770 0.81 Profit of 1,405 on sale
2025-04-08SELL-1,2940.5000.590 0.581USD -752 0.82 Profit of 303 on sale
2025-04-04SELL-3,2350.4200.460 0.456USD -1,475 0.82 Profit of 1,188 on sale
2025-04-01BUY2,5880.4600.540 0.532USD 1,377 0.83
2025-03-31SELL-1,9410.4600.710 0.685USD -1,330 0.84 Profit of 293 on sale
2025-03-14SELL-10,3840.3700.370 0.370USD -3,842 0.91 Profit of 5,577 on sale
2025-03-07SELL-1,2980.3900.410 0.408USD -530 0.95 Profit of 701 on sale
2025-03-04SELL-6490.3200.340 0.338USD -219 0.98 Profit of 414 on sale
2025-02-25BUY1,2980.6600.710 0.705USD 915 1.01
2025-02-19SELL-6490.7400.790 0.785USD -509 1.03 Profit of 159 on sale
2025-02-13BUY1,9470.7400.750 0.749USD 1,458 1.05
2025-02-12BUY6490.7000.720 0.718USD 466 1.06
2025-02-11BUY2,5920.7000.750 0.745USD 1,931 1.07
2024-12-30SELL-3,2400.7200.770 0.765USD -2,479 1.18 Profit of 1,357 on sale
2024-11-18SELL-9,6180.9101.000 0.991USD -9,531 1.61 Profit of 5,957 on sale
2024-11-08SELL-6371.2701.320 1.315USD -838 1.66 Profit of 223 on sale
2024-10-21SELL-6371.9502.080 2.067USD -1,317 0.00 Loss of -1,317 on sale
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of LXRX

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19552,6949,9261,527,47336.2%
2025-09-18592,35626,4692,644,14922.4%
2025-09-17333,8391,4861,112,51830.0%
2025-09-16162,3491,000648,23825.0%
2025-09-15298,4030729,45140.9%
2025-09-12194,0670839,30323.1%
2025-09-11264,1910844,98431.3%
2025-09-10395,39831,133985,19540.1%
2025-09-09328,16601,032,16831.8%
2025-09-08223,5410677,31633.0%
2025-09-05328,0166,730952,52434.4%
2025-09-04548,1273,2011,021,49853.7%
2025-09-03295,333262637,10046.4%
2025-09-02538,50614,4021,762,21930.6%
2025-08-29345,8842,234859,80240.2%
2025-08-28728,29268,2031,114,23665.4%
2025-08-27310,7462,689726,71242.8%
2025-08-26154,1951,435477,69332.3%
2025-08-25240,93810729,45533.0%
2025-08-22356,76116,225894,16539.9%
2025-08-21221,5180930,55323.8%
2025-08-20354,653679900,66139.4%
2025-08-19546,688787996,66854.9%
2025-08-18266,6218,0301,107,43624.1%
2025-08-15647,84101,703,21038.0%
2025-08-14604,6391,5001,833,82733.0%
2025-08-13478,0706571,433,36933.4%
2025-08-12414,0531,3001,210,44534.2%
2025-08-11638,44901,255,07750.9%
2025-08-08381,2622001,766,49321.6%
2025-08-07866,6493,9351,504,68657.6%
2025-08-061,447,66923,7063,328,02643.5%
2025-08-051,235,28027,2511,934,35463.9%
2025-08-04556,7472,9561,279,32143.5%
2025-08-01251,250130613,46441.0%
2025-07-31588,6671,1201,252,38047.0%
2025-07-30487,7182,682984,83949.5%
2025-07-29509,4546,8001,082,02447.1%
2025-07-281,021,8142,4001,931,04152.9%
2025-07-25578,6563,4101,498,49738.6%
2025-07-24509,91310,8381,778,66528.7%
2025-07-23586,37801,473,38639.8%
2025-07-22787,43771,4892,453,02832.1%
2025-07-211,378,016111,2612,150,15164.1%
2025-07-181,802,764121,4313,428,40852.6%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.